ACMSD: A Promising Drug Target for Cancer Treatment (G130013)

Target Name: ACMSD

NCBI ID: G130013

ACMSD

ACMSD: A Promising Drug Target for Cancer Treatment

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals. The development of new cancer treatments is crucial for improving survival rates and quality of life. One of the promising drug targets for cancer treatment is the ACMSD (2 -amino-3-carboxymuconate-6-semialdehyde decarboxylase), an enzyme involved in the metabolism of aromatic amino acids, which are vital for the growth and development of cancer cells. In this article, we will discuss the ACMSD, its function, potential as a drug target, and current research in this field.

ACMSD: The Enzyme for Aromatic Amino Acid Metabolism

ACMSD is an enzyme located in the nucleotide excision repair (NER) complex, which is responsible for the repair of DNA damage caused by various forms of cancer treatments, including chemotherapy and radiation therapy. The NER complex is a complex of DNA repair enzymes, including ACMSD, which work together to repair the most common type of DNA damage, called single-strand damage.

ACMSD is a critical enzyme involved in the NER process, as it helps to remove the amino acid mutated in the DNA, which can result from damage caused by various forms of cancer treatments. It does this by catalyzing the decarboxylation of the amino acid alanine, which is crucial for the NER complex to function properly.

ACMSD as a Drug Target

The potential use of ACMSD as a drug target is based on its unique structure and its involvement in the NER process. Because of its crucial role in the NER process, ACMSD has been targeted by various drug developers as a potential cancer treatment agent.

One of the main advantages of ACMSD as a drug target is its ease. Because ACMSD is an enzyme involved in the NER process, inhibiting its activity can lead to a range of potential side effects, such as DNA damage, cell death, and cancer growth. This is similar to the mechanism of action of many anti-cancer drugs, which work by inhibiting the growth and division of cancer cells.

Another advantage of ACMSD is its specificity. Currently, there are only a few drugs that are known to inhibit ACMSD, making it an attractive target for drug developers. These drugs have been shown to effectively inhibit ACMSD's activity and have been shown to have clinical potential benefits in cancer treatment.

Current Research

Current research into ACMSD as a drug target is ongoing, with several studies being conducted to investigate its potential as a cancer treatment agent. These studies have focused on the use of small molecules, such as inhibitors, to inhibit ACMSD's activity.

One of the most promising compounds that has been shown to inhibit ACMSD's activity is called ML-801. ML-801 is a small molecule inhibitor that has been shown to inhibit ACMSD's activity in cell cultures and in animal models of cancer treatment. Further clinical trials are being conducted to evaluate the safety and efficacy of ML-801 as a cancer treatment agent.

Another compound that has been shown to inhibit ACMSD's activity is called IDN-1022. IDN-1022 is a small molecule inhibitor that has been shown to inhibit ACMSD's activity in cell cultures and in animal models of cancer treatment. Further clinical trials are being conducted to evaluate the safety and efficacy of IDN-1022 as a cancer treatment agent.

Conclusion

In conclusion, ACMSD is an enzyme involved in the NER process that has been shown to be a promising drug target for cancer treatment. Its strength and specificity make it an attractive target for drug developers, and several compounds, such as ML-801 and IDN-1022, have been shown to inhibit its activity in cell cultures and in animal models of cancer treatment. Further clinical trials are being conducted to evaluate the safety and efficacy of these compounds as a cancer treatment agent. With the potential for new cancer treatments, the future of cancer

Protein Name: Aminocarboxymuconate Semialdehyde Decarboxylase

Functions: Converts alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS) to alpha-aminomuconate semialdehyde (AMS). ACMS can be converted non-enzymatically to quinolate (QA), a key precursor of NAD, and a potent endogenous excitotoxin of neuronal cells which is implicated in the pathogenesis of various neurodegenerative disorders. In the presence of ACMSD, ACMS is converted to AMS, a benign catabolite. ACMSD ultimately controls the metabolic fate of tryptophan catabolism along the kynurenine pathway

The "ACMSD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACMSD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets